Bickerstaff MCM, Botto M, Hutchinson WL, Herbert J, Tennent GA, et al. (1999) Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 5: 694–697.
[2]
Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, et al. (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 19: 56–59.
[3]
Bygrave A, Rose K, Warren J, Cortes-Hernandez J, Rigby R, et al. (2004) Spontaneous autoimmunity in 129 and C57BL/6 mice—Implications for autoimmunity described in gene-targeted mice. PLoS Biol 2: e243. doi: 10.1371/journal.pbio.0020243.
[4]
Mestas J, Hughes CCW (2004) Of mice and not men: Differences between mouse and human immunology. J Immunol 172: 2731–2738.
[5]
Morahan G, Morel L (2002) Genetics of autoimmunity in patients and models. Curr Opin Immunol 14: 803–811.
[6]
Mouse Genome Sequencing Consortium (2002) Initial sequencing and comparative analysis of the mouse genome. Nature 420: 520–562.
[7]
Obara T, Tanaka T, Stockert E, Good RA (1979) Autoimmune and lymphoproliferative disease in (B6-GIX+ × 129)F1: Relation to naturally occurring antibodies against murine leukemia virus-related surface antigens. Proc Natl Acad Sci U S A 76: 5289–5293.
[8]
Santiago-Raber ML, Lawson BR, Dummer W, Barnhouse M, Koundouris S, et al. (2001) Role of cyclin kinase inhibitor p21 in systemic autoimmunity. J Immunol 167: 4067–4074.
[9]
Smithies O (1993) Animal models of human genetic diseases. Trends Genet 9: 112–116.
[10]
Wakeland EK, Wandstrat AE, Liu K, Morel L (1999) Genetic dissection of systemic lupus erythematosus. Curr Opin Immunol 11: 701–707.
[11]
Wassarman PM, DePamphilis ML (1993) Guide to techniques in mouse development. San Diego: Academic Press. editors.
